Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab safety in advanced renal cell carcinoma
NCT02596035Phase 4Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2016
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nivolumab in renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Primary endpoint: Percentage of Participants Who Experienced High-Grade (Grade 3-4 and Grade 5) Immune Mediated Adverse Events at 100 days. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02596035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596035.